Cancer - Y-mAbs Therapeutics

Cancer

Status:

Active, open to accrual

ClinicalTrials.gov:

NCT05130255

Phase 1 trial with GD2-SADA:177Lu-DOTA Drug Complex in patients with recurrent or refractory metastatic solid tumors known to express GD2, including Small Cell Lung Cancer, High Risk Neuroblastoma, Sarcoma and Malignant Melanoma

Drug

GD2- SADA

Condition

small cell lung cancer, neuroblastoma, sarcoma, osteosarcoma, soft tissue sarcoma, agniosarcoma, ewing sarcoma, malignant melanoma